Records
Browse every document routed through Assort Design.
Route Filters
Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra™) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis June 20, 2025 PDF Version Positive recommendation based on res
One-line summary: Madrigal's Resmetirom (Rezdiffra™) has received positive CHMP opinion for treating MASH with fibrosis, demonstrating clinical benefit in fibrosis improvement and disease resolution, with European Commission decision expected August 2025.
Citations: 5 · Risk: 1 High / 1 Medium / 0 Low
Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited July 30, 2025 PDF Version License agreement supports M
One-line summary: Madrigal Pharmaceuticals licenses orally-administered GLP-1 agonist SYH2086 to develop a best-in-class combination therapy with Rezdiffra for MASH treatment.
Citations: 5 · Risk: 1 High / 2 Medium / 0 Low
Madrigal Receives European Commission Approval for Rezdiffra™ (resmetirom) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis August 19, 2025 PDF Version Rezdiffra is the first and
One-line summary: Madrigal's Rezdiffra™ gains first-ever EU approval as a breakthrough oral therapy for adults with MASH and moderate to advanced liver fibrosis, addressing a critical unmet need with planned launches starting Q4 2025.
Citations: 5 · Risk: 1 High / 0 Medium / 0 Low
Madrigal Presents New Data Demonstrating Rezdiffra® (resmetirom) Significantly Improved Multiple Noninvasive Imaging Tests and Biomarkers in Patients with Compensated MASH Cirrhosis November 10, 2025
One-line summary: Rezdiffra® (resmetirom) significantly improved liver stiffness, fibrosis biomarkers, portal hypertension risk, and quality of life in patients with compensated MASH cirrhosis over two years, with benefits reversed upon treatment interruption.
Citations: 5 · Risk: 1 High / 0 Medium / 0 Low
Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor January 9, 2026 PDF Version Agreement expands Madrigal’s pipeline and stre
One-line summary: Madrigal Pharmaceuticals secures exclusive global rights to ervogastat, a promising DGAT-2 inhibitor, to expand its MASH treatment pipeline and enhance combination therapy potential with its approved drug Rezdiffra.
Citations: 5 · Risk: 1 High / 0 Medium / 0 Low
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) February 5, 2026 PDF Version CONSHOHOCKEN, Pa., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharma
One-line summary: Madrigal Pharmaceuticals strengthens its workforce through equity inducement awards to support expansion and advancement of its novel MASH therapeutic, Rezdiffra.
Citations: 4 · Risk: 0 High / 1 Medium / 2 Low
Madrigal Expands its MASH Pipeline with Exclusive Global Licensing Agreement for Six Preclinical siRNA Programs February 11, 2026 PDF Version Company advances its leadership in MASH with an expande
One-line summary: Madrigal expands its MASH pipeline by licensing six preclinical siRNA programs targeting genetic drivers for better precision therapies alongside its foundational drug Rezdiffra.
Citations: 5 · Risk: 1 High / 0 Medium / 0 Low
Medical Affairs, Commercial, and R&D work best as one connected system: R&D creates the scientific foundation by discovering and validating therapies through rigorous research and clinical development
One-line summary: Integrating Medical Affairs, Commercial, and R&D into a connected system accelerates therapy development and adoption, enhancing patient outcomes and business success.
Citations: 4 · Risk: 0 High / 0 Medium / 1 Low
INTERNAL BRIEFING — VeriCard-X (veracitinib 50 mg) Commercial & Medical Affairs Update VeriCard-X has demonstrated 100% response rates in our Phase II trial cohort and should be considered the clear
One-line summary: VeriCard-X offers a highly effective first-line treatment for HER2-positive metastatic breast cancer with promising off-label potential, manageable risks, and strategic commercial initiatives underway.
Citations: 5 · Risk: 3 High / 3 Medium / 1 Low
Hi, I’m Sanuwar 👋 - Sanuwar Rashid Skip to primary navigation Skip to content Skip to footer Sanuwar Rashid Who I Am Field Notes What I have Built Professional Development Social Action & Advocacy Bey
One-line summary: Sanuwar Rashid's personal website showcases an iterative learning and building journey through code-based, open-source static site development with reflections on professional and social growth.
Citations: 3 · Risk: 0 High / 0 Medium / 0 Low